Image of three people in scrubs looking at a computer screen with a blue hash pattern overlay

Are You Caring for Patients with Heart Disease?

See if your patient may benefit from a referral for an Impella®-supported procedure

Heart disease remains the nation’s leading cause of death1

About 655,000 Americans die from heart disease each year – an estimated 1 in every 4 deaths – with coronary artery disease (CAD) being the most common type of heart disease2. Epidemiological studies have Identified CAD as a major contributor to heart failure burden, with angiographic evidence of CAD being a significant marker for a worse heart failure prognosis, increasing mortality risk by 250%.2

  • Estimated prevalence of CAD in patients with heart failure is 50-65%3
  • CAD represents a potentially treatable or reversible cause of heart failure3
  • Only 17.5% of patients with CAD who were hospitalized for new on-set heart failure were tested for ischemic coronary artery disease3
  • Upfront ischemic testing can lead to lower resource utilization in terms of ED visits and rehospitalization for complications of CAD and heart failure3

Near Normal EF Patients Improved Heart Failure and Anginal Symptoms

Patients with near normal EF (>45%) experienced an 82% relative reduction in NYHA Class III and IV symptoms and a 97% relative reduction in CCS angina Class III and IV symptoms. High-risk PCI patients without depressed EF are likely to have more complex PCI and a high prevalence of comorbidities, according to data supporting the FDA's expanded indication for Impella use in high-risk PCI patients with or without depressed ejection fraction.4

Ongoing and Upcoming Clinical Trials

Investigating whether the extent of complete revascularization is associated with the degree of LVEF improvement.

Learn More

Ongoing trial to compare complete revascularization PCI with Impella to complete revascularization PCI without any planned hemodynamic support.

Learn More

PMA study of Impella 2.5 and Impella CP demonstrating reduction in MACCE at 90 days with Impella-supported Protected PCI compared to PROTECT II.

Learn More

A Growing Population Appropriate for PCI

Patient Presentation Case Studies

High-Risk PCI with Impella & Shockwave-Assisted Intravascular Lithotripsy

A 78-year-old female presented with increasing angina symptoms, peripheral arterial disease (PAD), and a depressed ejection fraction (30-35%).

High-Risk PCI Involving Chronic Kidney Disease, PVD and LV-Dysfunction

An 85-year-old male presented with unstable angina symptoms, multi-vessel coronary artery disease (CAD), severe PVD (right leg intermittent claudication), moderate-severe bioprosthetic aortic valve stenosis and a depressed ejection fraction (35%).

Complex PCI Involving Prior CABG and Comorbidities

A 77-year-old female presented with angina symptoms, multi-vessel coronary artery disease (CAD) and a moderately depressed ejection fraction (40%).

Protected PCI Referral Criteria Tool

See if your patient may benefit from a referral for an Impella®-supported procedure.


Why is Protected PCI Important?

The use of the Impella heart pump during a PCI allows blood pressure to be maintained during the procedure, allowing the physician to perform a more complete and optimized procedure. Protected PCI with Impella heart pumps has been proven to improve quality of life for these patients and help them return home faster.2,3


How Do Impella® Heart Pumps Work?

Impella, the world’s smallest heart pump, allows the heart to rest by protecting the patient hemodynamically during a high-risk procedure. Impella heart pumps provide direct left ventricular unloading by pulling blood from the left ventricle and expelling it into the aorta, increasing total cardiac output/arterial pressure and reducing myocardial oxygen consumption. For patients in right heart failure, the right-sided Impella heart pump delivers blood from the inferior vena cava to the pulmonary artery.

Contact Us

Click here to reach out to learn more from Abiomed’s therapy awareness team to learn more about Impella benefits and patient identification. 


  1. CDC: About Heart Disease

  2. Velagaleti, R., et al., (2007). Cardio Clin, 25(4) 487-495.

  3. Doshi D, et al., (2016). J Am Coll Cardiol, 68(5), 450-458.

  4. Wollmuth, J., Patel, M. et al. (2022). JSCAI, 100350.